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Research on human has been a critical pillar for the advancement of medical knowledge including the development of novel vaccines and drugs. Yet the legacy of scientific experiments on human is far to be 
without controversies. Unethical scientific experiments have been conducted 
on enslaved persons, World War II prisoners, and even in postwar period 
where cases of unethical experiments were reported on prisoners, mentally 
disabled, and ethnic minorities such us the Tuskegee Syphilis study [1] con-
ducted between 1932 and 1972 in the United States. In Africa, suspected 
unethical clinical trials have been reported. For example, in 2001, the phar-
maceutical company Pfizer has been accused over informed consent issues and unethical trial in Nigeria 
during the meningitis epidemic in 1996 [2].
To prevent unethical practices in medical research, the World Medical Association (WMA) through the 
Declaration of Helsinki has established since 1964 guidelines for medical researchers to balance the need 
to generate medical knowledge with the need to protect the health and interests of research participants 
[3]. In 1978, following the infamous Tuskegee Syphilis Study, the National Commission for the Protec-
tion of Human Subjects of Biomedical and Behavioral Research of the United States has stated moral prin-
ciples and guidelines for the protection of human subjects summarized in The Belmont Report and avail-
able as DHEW (Department of Health Education and Welfare) Publication No. (OS) 78-0013 and No. 
(OS) 78-0014 [4,5].
COVID-19 AND VACCINE AND MEDICINE DEVELOPMENT
Still counting, it has been several months since the COVID-19 (novel coronavirus, also known as 2019-
nCoV or SARS-CoV-2) outbreak disrupts the world [6]. One of the evident solutions against this outbreak 
is the development of an effective vaccine and/or a medicine to protect our human community. While wait-
ing for an effective treatment, worldwide we are all experiencing uncomfortable rigor policies such as cities 
and countries lockdowns coupled with social distancing policies and the use of personal protective equip-
ment. All these new normal realities are not for sure our main expectations when we kicked off a new de-
cade with lot of promises.
Due to the high contagiousness of COVID-19 [7] and the lack of an effective medicine, governments and 
companies are urging their teams to develop new vaccine and therapy with the noble mission to protect 
us from COVID-19 and preserve our economic achievements. In view of the current global pandemic 
situation, as a young scientist, I can understand the pressure my colleagues from public and private in-
stitutions are facing to develop rapidly vaccine and medicine. It is definitively a tough race.
The traditional workflow to develop drugs and vaccines takes from several months to years before reach-
ing the market. Throughout preclinical experiments, scientists determine the safety and effectiveness of 
candidate vaccines and drugs. After this first step, several phases of clinical trials are followed by enroll-
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ing patients and volunteers to participate in small pilot studies to confirm the 
safety of the treatment protocol before scaling up to large cohort studies for 
further confirmatory tests. During clinical trials, one of the responsibilities of 
scientists is to determine the appropriateness of clinical trial parameters such 
as randomization in addition to the design of a risk-free placebo control espe-
cially during disease outbreaks with high contagiousness and mortality rate. 
Other responsibilities from scientists are to ensure that the proposed method-
ologies of the trial are consented by the participative communities.
There is no doubt that scientists are trained with strong ethical values. How-
ever, under the current pandemic circumstances, we cannot exclude the pos-
sibilities that some scientists violate clinical trials rules and guidelines to accelerate new vaccine and med-
icine development. For instance, identifying countries with weak clinical trial guidelines and policies 
could be preferred for unethical and fast clinical trials. Currently, there is no uniform policy for conduct-
ing trials across the world, this means every government is responsible to establish their own policies. 
Low-income countries, notably Africans, could be preferred as a basis for experimentations on human 
subjects due to the lack of stringent policies in comparison to their high-income counterparts.
During clinical trials, healthy volunteers, and sick participants who are often powerless, expect from sci-
entists and physicians to incorporate strong ethics and bioethics rules in their experimental design. From 
their governments, these participants expect an establishment of critical and stringent guidelines and rec-
ommendations for an ethically acceptable trial. It is the responsibility of the governments to fully under-
stand the risks of clinical trials on their population in the goal to prevent unwanted and unwarranted 
setbacks especially during the current pandemic situation.
Under the current pandemic circumstances, our moral rationale could be seriously challenged as scien-
tists; however, these moments could represent an opportunistic timeframe for some governments to def-
initely upgrade their clinical trial policies and guidelines because of ongoing and upcoming clinical trials.
For instance, on 1 April 2020, on the French national television “The News Channel”, it was with worry 
that I heard Dr. Camille Locht, the head of the Center for Infection and Immunity of Lille and Dr. Jean 
Paul Mira, the head of the intensive care at the Cochin Hospital in Paris, publicly discussing about con-
ducting vaccine clinical trials in Africa to explore potential preventive effects of the existing vaccine BCG 
on COVID-19 with the main argument that Africa “anyhow” doesn’t have the capabilities to face this cri-
sis representing therefore an opportunity to conduct exper-
imentations using real placebo and the vaccine BCG at large 
scale thus reaching satisfactory statistical value [8]. The ar-
gument to target Africa for clinical trials because of weak ca-
pabilities such as the lack of masks, treatments and ventila-
tors systems is ethically unacceptable. Some could ask why 
to prioritize Africa in clinical trials while it was not the epi-
center of the disease?
Although these are uncertain times for all of us with limited 
resources and capacities, public health officials, policy mak-
ers, researchers, and physicians should place human at the 
center of their decision-making processes. This period 
should not be the opportunity to discriminate some of the 
world population, as one may think that clinical trials could 
be performed on them without the same stringent measures 
as on other population. This is the moment for us to use our 
bioethics lessons and moral rationale in every decision-mak-
ing process. It is ethically unacceptable to leverage the lack 
of capabilities and poverty to satisfy our desire to understand 
scientific mechanisms and examine the effectiveness of drug 
and vaccine candidates. Although these are tough times, sci-
entists and physicians have to ensure that their trial study 
proposals are scientifically and ethically valid and respect the 
participant’s rights and safety. These studies should also align 
with the guidelines of national regulatory agencies in Africa. Photo: From the author's own collection, used with permission.
In view of the ongoing and up-
coming COVID-19 clinical tri-
als in Africa, governments and 
African Union should establish 
a watchdog committee to su-
pervise trials and upgrade trial 
guidelines.
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Additional layers of clinical trials supervision from international organizations such as the world health 
Organization (WHO) and the World Medical Association (WMA) could help to enforce the trial guide-
lines.
At the end of the day, we need clinical trials and we can understand that some scientists and medical doc-
tors could be attracted to leverage the lack of capabilities and weak public health policies in some countries 
to reach satisfactory statistical values. Ethically, as researchers, we shall pursue our scientific mission against 
COVID-19 without enrolling exploitatively vulnerable population to clinical trials for the benefit of others.
CONCLUSION
During this pandemic era, unethical trial might occur only if the policy and the surveillance of the trial 
are weak. Therefore, the African governments, the African Union, the WHO, and the WMA should co-
ordinate their effort to ensure a transparent process of ongoing and upcoming clinical trials in Africa. It 
is also the time for Africa governments to draft a unique and stringent continental guideline for clinical 
trials and a detailed protocol to assess clinical studies validities. The policymakers and governments should 
take a close look at clinical trial proposals to avoid potential unethical scientific experiments. Although a 
critical time, as scientist, we cannot afford to repeat the dark side of clinical trials legacy.
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